WO2005115304A3 - Utilisation d'inhibiteurs de c-kit pour le traitement de la fibrodysplasie - Google Patents

Utilisation d'inhibiteurs de c-kit pour le traitement de la fibrodysplasie Download PDF

Info

Publication number
WO2005115304A3
WO2005115304A3 PCT/IB2005/001371 IB2005001371W WO2005115304A3 WO 2005115304 A3 WO2005115304 A3 WO 2005115304A3 IB 2005001371 W IB2005001371 W IB 2005001371W WO 2005115304 A3 WO2005115304 A3 WO 2005115304A3
Authority
WO
WIPO (PCT)
Prior art keywords
kit inhibitors
fibrodysplasia
treating
treating fibrodysplasia
inhibitors
Prior art date
Application number
PCT/IB2005/001371
Other languages
English (en)
Other versions
WO2005115304A2 (fr
Inventor
Alain Moussy
Jean-Pierre Kinet
Original Assignee
Ab Science
Alain Moussy
Jean-Pierre Kinet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science, Alain Moussy, Jean-Pierre Kinet filed Critical Ab Science
Publication of WO2005115304A2 publication Critical patent/WO2005115304A2/fr
Publication of WO2005115304A3 publication Critical patent/WO2005115304A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Abstract

L'invention concerne un procédé qui permet de traiter la fibrodysplasie telle que la fibrodysplasie ossifiante progressive, selon lequel on administre un composé capable de dépléter les mastocytes ou un composé inhibant la dégranulation des mastocytes à un humain qui en a besoin. Les composés tels que le composé précité peuvent être choisis parmi des inhibiteurs de c-kit et, en particulier, parmi des inhibiteurs de c-kit puissants, sélectifs et non toxiques. De préférence, l'inhibiteur n'est pas capable de promouvoir la mort des cellules dépendantes de l'IL-3 cultivées en présence d'IL-3.
PCT/IB2005/001371 2004-05-24 2005-04-19 Utilisation d'inhibiteurs de c-kit pour le traitement de la fibrodysplasie WO2005115304A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57334504P 2004-05-24 2004-05-24
US60/573,345 2004-05-24

Publications (2)

Publication Number Publication Date
WO2005115304A2 WO2005115304A2 (fr) 2005-12-08
WO2005115304A3 true WO2005115304A3 (fr) 2006-04-06

Family

ID=35276073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/001371 WO2005115304A2 (fr) 2004-05-24 2005-04-19 Utilisation d'inhibiteurs de c-kit pour le traitement de la fibrodysplasie

Country Status (1)

Country Link
WO (1) WO2005115304A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2358A (en) 2005-05-09 2012-01-30 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use.
SI3255061T1 (sl) 2006-11-03 2021-09-30 The Board Of Trustees Of The Leland Stanford Junior University Selektivno imunsko osiromašenje niše endogenih matičnih celic za vsaditev
JP2010528019A (ja) 2007-05-22 2010-08-19 アキリオン ファーマシューティカルズ，インコーポレーテッド ヘテロアリール置換チアゾール
US20110105436A1 (en) * 2008-03-10 2011-05-05 Auckland Uniservices Limited Heteroaryl compounds, compositions, and methods of use in cancer treatment
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
CA2728228A1 (fr) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Composes inhibiteurs de l'oxindolyle
AU2009271003A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolylpyrimidine compounds as HDAC and/or CDK inhibitors
EP2303881A2 (fr) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Composés inhibiteurs hétérocycliques condensés d'histone déacétylase et/ou de kinases cycline-dépendantes
NZ590747A (en) 2008-07-28 2012-11-30 Gilead Sciences Inc Cycloalkylidene and heterocycloalkylidene hdac inhibitor compounds
WO2010144378A2 (fr) 2009-06-08 2010-12-16 Gilead Colorado, Inc. Composés inhibiteurs de hdac de cycloalkylcarbamate-benzamide-aniline
KR20120031170A (ko) 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
MX361414B (es) 2010-09-01 2018-12-05 Univ Jefferson Composición y método para reparación y regeneración muscular.
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
KR102486607B1 (ko) 2016-06-08 2023-01-11 클레멘티아 파마슈티컬즈, 인크. 이소성 골화를 치료하는 방법
SG10202105186XA (en) 2016-11-16 2021-06-29 Clementia Pharmaceuticals Inc Methods for treating multiple osteochondroma (mo)
US11786557B2 (en) 2017-10-02 2023-10-17 Fred Hutchinson Cancer Center Luteinizing hormone receptor binding agents and luteinizing hormone agonists to identify, expand, ablate and modify stem cells
CN115697979A (zh) 2020-04-24 2023-02-03 拜耳公司 作为用于免疫激活的dgkzeta抑制剂的取代的氨基噻唑类

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010391A1 (fr) * 1998-08-25 2000-03-02 Medco Research, Inc. Utilisation d'antagonistes de recepteurs d'adenosine a3 pour inhiber la croissance tumorale
WO2002045652A2 (fr) * 2000-12-04 2002-06-13 Merck & Co., Inc. Inhibiteurs de tyrosine-kinase
WO2002053101A2 (fr) * 2000-12-29 2002-07-11 Alteon, Inc. Procede de traitement de troubles fibrogenes et autres symptomes de type ivc
WO2002094842A2 (fr) * 2001-05-24 2002-11-28 University Of Western Ontario Regulation de la myogenese par modulation de l'activite de la proteine-kinase p38 associee aux membranes
WO2003002109A2 (fr) * 2001-06-29 2003-01-09 Ab Science Utilisation d'inhibiteurs de tyrosine kinase destines a traiter des maladies auto-immunes
WO2004014903A1 (fr) * 2002-08-02 2004-02-19 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles et leur utilisation en tant que inhibiteurs de c-kit

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010391A1 (fr) * 1998-08-25 2000-03-02 Medco Research, Inc. Utilisation d'antagonistes de recepteurs d'adenosine a3 pour inhiber la croissance tumorale
WO2002045652A2 (fr) * 2000-12-04 2002-06-13 Merck & Co., Inc. Inhibiteurs de tyrosine-kinase
WO2002053101A2 (fr) * 2000-12-29 2002-07-11 Alteon, Inc. Procede de traitement de troubles fibrogenes et autres symptomes de type ivc
WO2002094842A2 (fr) * 2001-05-24 2002-11-28 University Of Western Ontario Regulation de la myogenese par modulation de l'activite de la proteine-kinase p38 associee aux membranes
WO2003002109A2 (fr) * 2001-06-29 2003-01-09 Ab Science Utilisation d'inhibiteurs de tyrosine kinase destines a traiter des maladies auto-immunes
WO2004014903A1 (fr) * 2002-08-02 2004-02-19 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles et leur utilisation en tant que inhibiteurs de c-kit

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GANNON FRANCIS H ET AL: "Mast cell involvement in fibrodysplasia ossificans progressiva", HUMAN PATHOLOGY, vol. 32, no. 8, August 2001 (2001-08-01), pages 842 - 848, XP002354246, ISSN: 0046-8177 *
JOB-DESLANDRE CHANTAL: "Inherited ossifying diseases.", JOINT, BONE, SPINE : REVUE DU RHUMATISME. MAR 2004, vol. 71, no. 2, March 2004 (2004-03-01), pages 98 - 101, XP002354247, ISSN: 1297-319X *

Also Published As

Publication number Publication date
WO2005115304A2 (fr) 2005-12-08

Similar Documents

Publication Publication Date Title
WO2005115304A3 (fr) Utilisation d'inhibiteurs de c-kit pour le traitement de la fibrodysplasie
WO2005102346A3 (fr) Utilisation des inhibiteurs de c-kit pour le traitement de la fibrose
WO2005016323A3 (fr) Utilisation d'inhibiteurs de c-kit pour le traitement du diabete de type ii
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
SG179418A1 (en) Inhibitors of the hedgehog pathway
WO2008033562A3 (fr) Composés inhibiteurs de kinases
MX2009006535A (es) Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
WO2005117867A3 (fr) Heterocycles monocycliques commes inhibiteurs de kinases
WO2010021680A3 (fr) Inhibiteurs de la bêta-sécrétase
ZA200902384B (en) Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
WO2009140621A3 (fr) Compositions et procédés ayant trait aux composés activant le facteur de transcription de choc thermique et cibles correspondantes
MX2012000766A (es) Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina.
WO2007026251A8 (fr) Utilisation d'inhibiteurs combines c-kit/fgfr3 pour le traitement du myelome multiple
TW200637847A (en) Substituted triazole derivatives as oxytocin antagonists
GEP20125511B (en) Mapk/erk kinase inhibitors
WO2007133865A3 (fr) Composés organiques et leurs utilisations
WO2003028711A3 (fr) Utilisation d'inhibiteurs de c-kit pour traiter un myelome
MY162022A (en) Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors
WO2007111948A3 (fr) Inhibiteurs de prényltransférases protéiques
WO2006023866A3 (fr) Acides thiazolo-naphthyliques
MX2009006256A (es) Composiciones intensificadoras inhibidoras de corrosion y metodos relacionados.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase